Table 2 Clinical application of ctDNA detection in diffuse large B cell lymphoma
From: Circulating tumor DNA in lymphoma: technologies and applications
Reference | Origin of ctDNA | Technologies | Patient counts (Lymphoma subtypes) | Clinical applications |
|---|---|---|---|---|
Daigle et al. [114] | Plasma | 62-gene panel NGS | 185 (DLBCL, FL) | Treatment response |
Rivas-Delgado et al. [113] | Plasma | 112-gene panel NGS | 100 (DLBCL) | Treatment response; Prognosis |
Rossi et al. [32] | Plasma | 59-gene panel CAPP-seq | 50 (DLBCL) | Treatment response; MRD monitoring |
Sworder et al. [117] | Plasma | Custom 608Â kb oligonucleotide panel CAPP-seq | 138 (R/R LBCL) | Treatment response; Prognosis |
Bruscaggin et al. [118] | Plasma | Custom 608Â kb oligonucleotide panel CAPP-seq | 67 (DLBCL, FL, RS) | Treatment response; Prognosis |
Meriranta et al. [122] | Plasma | 126-gene panel NGS | 101 (DLBCL, PMBCL, FL3b, THRLBCL) | Treatment response; Prognosis |
Esfahani et al. [42] | Plasma | EPIC-seq targeting on 236 TSS regions | 114 (DLBCL) | Prognosis |
Olszewski et al. [170] | Cerebrospinal fluid | IgHTS | 37 (Aggressive lymphoma) | Diagnostic |
Alig et al. 2021 [124]. | Plasma | Custom 608Â kb oligonucleotide panel CAPP-seq | 267 (DLBCL, TRHRLBCL) | Prognosis |
Roschewski et al. [120] | Plasma | NGS targeting on IgH and IgK locus | 126 (DLBCL) | MRD monitoring; Prognosis |
Kurtz et al. [107] | Plasma | 466-gene panel CAPP-seq | 217 (DLBCL, PMBL) | Prognosis |
Zou et al. [33] | Plasma | 188-gene panel NGS | 23 (DLBCL, HGBL, tFL) | Prognosis; MRD monitoring |
Frank et al. [121] | Plasma | IgHTS | 72 (DLBCL, TFL, PMBL) | Prognosis |
Herrera et al. [135] | Plasma | 320 kb panel NGS | 33 (R/R DLBCL) | Prognosis; MRD monitoring |
Kurtz et al. [104] | Plasma | IgHTS | 75 (DLBCL, PTLD) | MRD monitoring |
Scherer et al. [41] | Plasma | Custom 608Â kb oligonucleotide panel CAPP-seq | 116 (DLBCL) | MRD monitoring; Prognosis |
Kurtz et al. [97] | Plasma | PhasED-Seq; Custom 608Â kb oligonucleotide panel CAPP-seq | 213 (B-cell lymphomas) | MRD monitoring |